{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:56:49Z","timestamp":1793642209629,"version":"4.5.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anti-transcriptional intermediary factor 1 gamma (TIF1\u03b3) antibody is a marker for predicting cancer association in patients with dermatomyositis (DM). The overall survival rate in DM patients with cancer was reported to be considerably worse than that in DM patients without cancer. However, the treatment for cancer-associated DM remains controversial, because the treatment priority between surgical resection for the tumor and internal treatments, including glucocorticoids, immunosuppressive agents, and intravenous immune globulin, has not been established.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report the case of a 57-year-old Japanese man diagnosed with anti-TIF1\u03b3 antibody-positive DM associated with ascending colon cancer. His clinical symptoms included facial and brachial edema, muscle weakness, dysphagia, myalgia, and rash. Physical examination revealed periorbital edema and Gottron's papules over his knuckles with brachial edema, and tenderness and weakness of the proximal limb muscles. The findings of hyperintense muscles in T2-weighted sequences of brachial contrast-enhanced magnetic resonance imaging and the infiltration of lymphocytic cells and CD4-positive lymphocytes from muscle biopsy were compatible with the diagnostic criteria for dermatomyositis. Anti-TIF1\u03b3 antibody was positive by immunoprecipitation assay. He first started internal treatment including intravenous immunoglobulin, steroid pulse, prednisolone, and azathioprine, followed by surgical resection for the tumor because of the elevation of creatine kinase and progression of dysphagia. However, clinical symptoms did not improve, and the patient died 6 months later.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We faced difficulties in determining the treatment priority between surgical resection and internal treatment for our case; therefore, this case would be educational for readers. We searched PubMed to identify English-language case reports of anti-TIF1\u03b3 antibody-positive dermatomyositis with malignancy and found 21 reported cases. We herein review and summarize previously reported cases of anti-TIF1\u03b3 antibody-positive DM with malignancy. Cancer screening is essential in patients with anti-TIF1\u03b3 antibody-positive dermatomyositis because it is associated with a high prevalence of malignancies. Our review revealed that initial surgical treatment should be recommended for better prognosis if the general condition allows.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13256-021-02664-1","type":"journal-article","created":{"date-parts":[[2021,3,21]],"date-time":"2021-03-21T20:03:38Z","timestamp":1616357018000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Anti-transcription intermediary factor 1 gamma (TIF1\u03b3) antibody-positive dermatomyositis associated with ascending colon cancer: a case report and review of the\u00a0literature"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4875-7470","authenticated-orcid":false,"given":"Ryohei","family":"Ono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Kumagae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Igasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Yoshizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izumi","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,22]]},"reference":[{"issue":"9388","key":"2664_CR1","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","volume":"362","author":"MC Dalakas","year":"2003","unstructured":"Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362(9388):971\u201382.","journal-title":"Lancet"},{"issue":"2","key":"2664_CR2","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1159\/000447289","volume":"10","author":"H Kamiyama","year":"2016","unstructured":"Kamiyama H, Niwa K, Ishiyama S, et al. Ascending colon cancer associated with dermatomyositis which was cured after colon resection. Case Rep Gastroenterol. 2016;10(2):338\u201343.","journal-title":"Case Rep Gastroenterol"},{"issue":"3","key":"2664_CR3","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/j.1365-2230.2007.02368.x","volume":"32","author":"T Yanagi","year":"2007","unstructured":"Yanagi T, Kato N, Yamane N, Osawa R. Bullous pemphigoid associated with dermatomyositis and colon carcinoma. Clin Exp Dermatol. 2007;32(3):291\u20134.","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"2664_CR4","first-page":"438","volume":"35","author":"C Andras","year":"2008","unstructured":"Andras C, Ponyi A, Constantin T, et al. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol. 2008;35(3):438\u201344.","journal-title":"J Rheumatol"},{"issue":"3","key":"2664_CR5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1212\/WNL.0000000000002863","volume":"87","author":"A Hida","year":"2016","unstructured":"Hida A, Yamashita T, Hosono Y, et al. Anti-TIF1-gamma antibody and cancer-associated myositis: a clinicohistopathologic study. Neurology. 2016;87(3):299\u2013308.","journal-title":"Neurology"},{"issue":"2","key":"2664_CR6","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/art.33379","volume":"64","author":"E Trallero-Araguas","year":"2012","unstructured":"Trallero-Araguas E, Rodrigo-Pendas JA, Selva-O\u2019Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(2):523\u201332.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"2664_CR7","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/1346-8138.12141","volume":"40","author":"K Ito","year":"2013","unstructured":"Ito K, Imafuku S, Hamaguchi Y, Fujimoto M, Nakayama J. Case report of anti-transcription intermediary factor-1-gamma\/alpha antibody-positive dermatomyositis associated with gastric cancer and immunoglobulin G4-positive pulmonary inflammatory pseudotumor. J Dermatol. 2013;40(7):567\u20139.","journal-title":"J Dermatol"},{"issue":"2","key":"2664_CR8","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/jdv.12797","volume":"30","author":"M Ogawa","year":"2016","unstructured":"Ogawa M, Sugiura K, Yokota K, Muro Y, Akiyama M. Anti-transcription intermediary factor 1-gamma antibody-positive clinically amyopathic dermatomyositis complicated by interstitial lung disease and breast cancer. J Eur Acad Dermatol Venereol. 2016;30(2):373\u20135.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"2664_CR9","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1186\/s12885-016-2715-1","volume":"16","author":"O Kubecek","year":"2016","unstructured":"Kubecek O, Soukup T, Paulik A, Kopecky J. Dermatomyositis with anti-TIF-1gamma antibodies as a presenting symptom of underlying triple-negative breast cancer: a case report. BMC Cancer. 2016;16(1):684.","journal-title":"BMC Cancer"},{"issue":"6","key":"2664_CR10","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1684\/ejd.2016.2856","volume":"26","author":"E Taki","year":"2016","unstructured":"Taki E, Shimizu M, Soeda Y, Shirai M, Muro Y. Anti-TIF1-gamma-positive young adult dermatomyositis with germ cell tumour. Eur J Dermatol. 2016;26(6):623\u20134.","journal-title":"Eur J Dermatol"},{"issue":"6","key":"2664_CR11","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1684\/ejd.2016.2857","volume":"26","author":"C Murase","year":"2016","unstructured":"Murase C, Muro Y, Nakanishi H, Katsuno M, Akiyama M. A patient with Parkinson\u2019s disease and dermatomyositis with serum anti-transcriptional intermediary factor 1-gamma antibody. Eur J Dermatol. 2016;26(6):617\u20138.","journal-title":"Eur J Dermatol"},{"issue":"8","key":"2664_CR12","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1111\/1346-8138.13579","volume":"44","author":"T Matsushita","year":"2017","unstructured":"Matsushita T, Takehara K, Oishi K, et al. Case of anti-transcriptional intermediary factor-1-positive dermatomyositis associated with breast cancer developing over 10 years. J Dermatol. 2017;44(8):972\u20133.","journal-title":"J Dermatol"},{"issue":"2","key":"2664_CR13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.4081\/reumatismo.2017.923","volume":"69","author":"B Palterer","year":"2017","unstructured":"Palterer B, Vitiello G, Cammelli D. First report of anti-TIF1gamma dermatomyositis in a patient with myelodysplastic syndrome. Reumatismo. 2017;69(2):75\u20137.","journal-title":"Reumatismo"},{"issue":"12","key":"2664_CR14","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1111\/ijd.13729","volume":"56","author":"N Kikuchi","year":"2017","unstructured":"Kikuchi N, Ohashi T, Miura T, Nishibu A, Yamamoto T. Triple cancers concurrently detected in a case of antitranscriptional intermediary factor-1gamma antibody-positive dermatomyositis. Int J Dermatol. 2017;56(12):1516\u20137.","journal-title":"Int J Dermatol"},{"issue":"1","key":"2664_CR15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/ddg.13394","volume":"16","author":"ML Schiffmann","year":"2018","unstructured":"Schiffmann ML, Warneke VS, Ehrchen J. Amyopathic dermatomyositis with anti-TIF1 gamma antibodies. J Dtsch Dermatol Ges. 2018;16(1):76\u20138.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"49","key":"2664_CR16","doi-asserted-by":"publisher","first-page":"e13563","DOI":"10.1097\/MD.0000000000013563","volume":"97","author":"K Karino","year":"2018","unstructured":"Karino K, Fujieda Y, Kawamura T, et al. Anti-TIF1gamma antibody predicted malignancy of thymic tumor with dermatomyositis as an \u201cautoimmune tumor marker\u201d: A case report. Medicine (Baltimore). 2018;97(49):e13563.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"2664_CR17","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1111\/1756-185X.13264","volume":"21","author":"M Teraishi","year":"2018","unstructured":"Teraishi M, Nakajima K, Ishimoto T, et al. Anti-transcription intermediary factor 1gamma antibody titer correlates with clinical symptoms in a patient with recurrent dermatomyositis associated with ovarian cancer. Int J Rheum Dis. 2018;21(4):900\u20132.","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"2664_CR18","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2169\/internalmedicine.1007-18","volume":"58","author":"T Aritomi","year":"2019","unstructured":"Aritomi T, Kido T, Nakano K, et al. Small cell lung cancer patient with anti-transcriptional intermediary factor 1gamma antibody who developed dermatomyositis after successful chemoradiotherapy. Intern Med. 2019;58(3):427\u201331.","journal-title":"Intern Med"},{"issue":"4","key":"2664_CR19","doi-asserted-by":"crossref","first-page":"e00412","DOI":"10.1002\/rcr2.412","volume":"7","author":"T Kato","year":"2019","unstructured":"Kato T, Ito S, Tsuzuki T, Watanabe D, Kubo A, Yamaguchi E. Small cell lung cancer and interstitial pneumonia associated with anti-transcriptional intermediary factor-1gamma-positive dermatomyositis. Respirol Case Rep. 2019;7(4):e00412.","journal-title":"Respirol Case Rep"},{"issue":"3","key":"2664_CR20","doi-asserted-by":"crossref","first-page":"e00403","DOI":"10.1002\/rcr2.403","volume":"7","author":"T Saraya","year":"2019","unstructured":"Saraya T, Tamura M, Kasuga K, Fujiwara M, Takizawa H. Lung adenocarcinoma and anti-transcriptional intermediary factor 1-gamma positive dermatomyositis complicated with spontaneous oesophageal rupture. Respirol Case Rep. 2019;7(3):e00403.","journal-title":"Respirol Case Rep"},{"issue":"3","key":"2664_CR21","doi-asserted-by":"crossref","first-page":"13030","DOI":"10.5070\/D3253043339","volume":"25","author":"D Varedi","year":"2019","unstructured":"Varedi D, Frigerio A, Scaife C, Hull C. A novel case of TIF1 gamma autoantibody positive dermatomyositis associated with a non-functional pancreatic neuroendocrine tumor. Dermatol Online J. 2019;25(3):13030.","journal-title":"Dermatol Online J"},{"issue":"1","key":"2664_CR22","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13256-019-2105-9","volume":"13","author":"C Shibata","year":"2019","unstructured":"Shibata C, Kato J, Toda N, et al. Paraneoplastic dermatomyositis appearing after nivolumab therapy for gastric cancer: a case report. J Med Case Rep. 2019;13(1):168.","journal-title":"J Med Case Rep"},{"issue":"1","key":"2664_CR23","first-page":"75","volume":"24","author":"G Zarkavelis","year":"2020","unstructured":"Zarkavelis G, Mauri D, Karassa F, et al. The cancer immunotherapy environment may confound the utility of anti-TIF-1gamma in differentiating between paraneoplastic and treatment-related dermatomyositis. Report of a case and review of the literature. ContempOncol (Pozn). 2020;24(1):75\u20138.","journal-title":"ContempOncol (Pozn)"},{"key":"2664_CR24","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.4702-20","author":"Y Nakanishi","year":"2020","unstructured":"Nakanishi Y, Yamaguchi K, Yoshida Y, et al. Coexisting TIF1gamma-positive primary pulmonary lymphoepithelioma-like carcinoma and anti-TIF1gamma antibody-positive dermatomyositis: a case report. Intern Med. 2020. https:\/\/doi.org\/10.2169\/internalmedicine.4702-20.","journal-title":"Intern Med"},{"key":"2664_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2020.06.008","author":"A Kuczmarska-Haas","year":"2020","unstructured":"Kuczmarska-Haas A, Burr AR, Witt JS, et al. Dramatic improvement of anti-transcription intermediary factor-1-gamma\/alpha antibody-positive dermatomyositis after stereotactic body radiotherapy to presumed lung primary-a case report. PractRadiatOncol. 2020. https:\/\/doi.org\/10.1016\/j.prro.2020.06.008.","journal-title":"PractRadiatOncol"},{"key":"2664_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-020-00974-7","author":"M Osaki","year":"2020","unstructured":"Osaki M, Tachikawa R, Ohira J, Hara S, Tomii K. Anti-transcriptional intermediary factor 1-gamma antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: a case report. Invest New Drugs. 2020. https:\/\/doi.org\/10.1007\/s10637-020-00974-7.","journal-title":"Invest New Drugs"},{"key":"2664_CR27","doi-asserted-by":"publisher","first-page":"e922004","DOI":"10.12659\/AJCR.922004","volume":"21","author":"M Sumazaki","year":"2020","unstructured":"Sumazaki M, Kaneko K, Ito M, et al. A case of dermatomyositis along with esophageal cancer and screening of serum transcriptional intermediary factor 1 gamma antibodies in various cancer patients. Am J Case Rep. 2020;21:e922004.","journal-title":"Am J Case Rep"},{"key":"2664_CR28","doi-asserted-by":"publisher","first-page":"992","DOI":"10.3389\/fimmu.2017.00992","volume":"8","author":"A Aussy","year":"2017","unstructured":"Aussy A, Boyer O, Cordel N. Dermatomyositis and immune-mediated necrotizing myopathies: a window on autoimmunity and cancer. Front Immunol. 2017;8:992.","journal-title":"Front Immunol"},{"issue":"1","key":"2664_CR29","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.autrev.2011.06.007","volume":"11","author":"I Marie","year":"2011","unstructured":"Marie I, Mouthon L. Therapy of polymyositis and dermatomyositis. Autoimmun Rev. 2011;11(1):6\u201313.","journal-title":"Autoimmun Rev"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-02664-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13256-021-02664-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-02664-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T21:50:30Z","timestamp":1671659430000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-021-02664-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,22]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2664"],"URL":"https:\/\/doi.org\/10.1186\/s13256-021-02664-1","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,22]]},"assertion":[{"value":"18 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient\u2019s next of kin for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors state that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"142"}}